Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
Lucy Gilbert, MD, MSc, professor, Department of Obstetrics & Gynecology and the Department of Oncology, McGill University and director of Gynecologic Oncology and Women’s Health Research Unite, McGill University Health Centre, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab (Avastin) in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
The overall response rate (ORR) was 47%, but in patients with high folate receptor alpha (FRα) expression, the ORR was 64%, which is a very encouraging finding. When looking at the subgroup of patients with high FRα-expression, the ORR is 59% among those with platinum-resistant disease, which is almost double what has been seen with other agents in this setting, says Gilbert. In the platinum-sensitive subset, the ORR is also encouraging at 69%.
Data for progression-free survival and duration of response were still immature, but almost half the patients remained on treatment after a median follow-up of 8.5 months.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More